Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Zenhale Mometasone/formoterol Asthma List with clinical criteria and/or conditions Complete
Zenhale (inhalation aerosol) Mometasone furoate and formoterol Asthma Do not list Complete
Zepatier Elbasvir/grazoprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Zeposia ozanimod Multiple Sclerosis, relapsing - remitting Do not reimburse Complete
Zeposia ozanimod Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Zepzelca lurbinectedin metastatic small cell lung cancer (SCLC) Do not reimburse Complete
Zevalin iIbritumomab tiuxetan Non-Hodgkin’s Lymphoma (NHL) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Zilbrysq zilucoplan Generalized myasthenia gravis (gMG) Active
Zinbryta Daclizumab beta Multiple Sclerosis, relapsing-remitting Reimburse with clinical criteria and/or conditions Complete
Zolgensma onasemnogene abeparvovec Spinal muscular atrophy (SMA), pediatrics Reimburse with clinical criteria and/or conditions Complete